News | Atherectomy Devices | February 08, 2017

LIBERTY 360 Study Demonstrates Sustained Benefit of Endovascular Intervention in Lower Extremity PAD

Following positive 30-day results, six-month data from the LIBERTY 360° study showed patients in all Rutherford Classes maintained improvement in PAD symptoms and quality of life

CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD

February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a presentation at the 29th International Symposium on Endovascular Therapy (ISET), Feb. 4-8 in Hollywood, Fla. The study is evaluating the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in treating patients with symptomatic lower extremity peripheral artery disease (PAD).

Physicians were able to use any U.S. Food and Drug Administration (FDA)-approved device, including CSI’s Diamondback 360 peripheral orbital atherectomy system. Findings continue to demonstrate that PVI can be successful in treating patients in all Rutherford Classes and suggest that “watchful waiting” for patients in Rutherford Class 2-3 and “primary amputation” for patients in Rutherford Class 6 may not be necessary.

Six-month study outcomes were presented at ISET by William Gray, M.D., of Main Line Health, Wynnewood, Pa. Additional authors on the abstract included Jihad Mustapha, M.D., of Metro Health Hospital, Wyoming, Mich.; George L. Adams, M.D., of Rex Healthcare, Raleigh, N.C.; Gary Ansel, M.D., of OhioHealth in Columbus, Ohio; and Michael Jaff, DO, president, Newton-Wellesley Hospital and professor of medicine, Harvard Medical School.

Some of the key six-month analysis conclusions discussed were:

  • Findings suggest that on average PVI can restore Rutherford 4-5 patients with critical limb ischemia (CLI) status (e.g. limb pain at rest, cold and/or numbness in feet, open or non-healing wounds on toes or foot) to moderate claudicant status (e.g. limb pain during movement); and
  • Through six months, these data demonstrate on average PAD patients (Rutherford 2-6) post-PVI have maintained good outcomes and positive changes in Rutherford classification

Change in Rutherford Classification Following Endovascular Intervention

 
Baseline
30 Days
6 Months

RC 2-3
2.8
1.3
1.4

RC 4-5
4.5
3.1
2.3

RC 6
6.0
5.5
4.6

 Table 1: All Rutherford Classes show improvement in RC from baseline to 30 days. RC4-5 and RC6 show continued improvement from 30 days to 6 months while RC2-3 maintains improvement at 6 months.

Said Gray, “Following endovascular intervention, we saw a marked improvement across all Rutherford Classes at six months: Rutherford 4-5 and Rutherford 6 patients showed continued improvement from 30 days to six months, while Rutherford 2-3 patients maintained improvement at six months. We also saw a high freedom from major adverse events across all classes. This suggests that endovascular intervention is an alternative treatment option in place of watchful waiting or even primary amputation.”

 
 

 
Rutherford Classification

RC 2-3
RC 4-5
RC 6

Freedom from (FF) MAE (6-month)
92.6%
81.2%
73.7%

FF Major Amputation
99.8%
96.8%
87.1%

FF Target Vessel Revascularization (TVR)
93.0%
83.1%
85.1%

FF Death
97.1%
95.3%
85.1%

Table 2: High freedom from MAEs at 6 months across all Rutherford Classes. Kaplan-Meier method used to estimate event-free rates. MAE defined as death (≤30 days after the procedure), major amputation of the target limb, and TVR.

According to VascuQoL, a patient-reported, PAD-specific health-related quality of life questionnaire, patients in the LIBERTY 360° study reported improved quality of life across all Rutherford Classes, including such measures as physical activity, symptoms and pain.

During a concurrent session at ISET, Mustapha highlighted the importance the LIBERTY 360° Rutherford 6 data will have on the endovascular field. He stated, “LIBERTY 360° is novel in that it addresses all Rutherford Classes, including Class 6, representing some of the most challenging and life-threatening PAD cases. Six-month data suggests that these patients can be treated successfully with endovascular interventions – a significant step in establishing a new standard of care for this difficult-to-treat population.”

Additionally it was shared that the recently released “2016 Guidelines on the Management of Patients with PAD” from the American Heart Association (AHA)/American College of Cardiology (ACC) support this data, stating:

  • Revascularization is a reasonable treatment option for patients with lifestyle-limiting claudication and an inadequate response to medical management and exercise; and
  • An evaluation for revascularization options should be performed by an interdisciplinary care team before amputation in the patient with CLI.

For more information: www.iset.org

Related Content

Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioImage-2 Study to Investigate Atherosclerotic Disease Progression
News | Cardiovascular Ultrasound| June 20, 2017
Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
Head-to-Head Study Validates Consistent Performance of Microcatheter FFR
News | FFR Catheters| May 31, 2017
Acist Medical Systems Inc. announced results from the ACIST-FFR Study demonstrating the consistent and correlative...
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices| May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
FFR-Search Registry Reveals Impact of Post-PCI Fraction Flow Reserve Measurement on Outcomes
News | FFR Catheters| May 30, 2017
Early results from the independent, physician-sponsored FFR-Search Registry revealed an association between post-...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients
News | Heart Failure| May 26, 2017
Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and...
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery| May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Overlay Init